Competitive Advantages
Which advantages over its rivals hold up, and why are they hard to copy?
PegBio holds a differentiation advantage over China's domestic GLP-1 developers, including Innovent's mazdutide, because Visepegenatide Injection is the only China-made GLP-1 to have completed Phase I and Phase II trials in the United States with no ethnic difference in efficacy shown. Innovent's mazdutide competes in China against Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
PegBio has established a Highly Effective Target Screening and Molecule Modifier Platform under the name HECTOR.
Market Outlook
Is its category moving in its favor or against it?
China's GLP-1 market is moving in PegBio's favor because analysts estimate it could reach RMB 100 billion by 2030, even as China had 60-70 late-stage GLP-1 pipeline assets as of February 2025 already competing with semaglutide and tirzepatide in diabetes and weight loss.
Within the market where PegBio sells Visepegenatide, over 140 million Chinese adults are living with type 2 diabetes, and current GLP-1 options are limited by injection frequency and gastrointestinal side-effects.
Memo
What is the investment case, and what must be true for it to hold?
PegBio can convert PB-119 into royalty revenue because the Visepegenatide injection won marketing approval from China's National Medical Products Administration in November 2025 and Shanghai Tenry Pharmaceutical has begun paying royalties on its commercialization, with a first payment of HK$61 million, provided the launch converts into sales, while Innovent's mazdutide, Novo Nordisk's Wegovy and Eli Lilly's Zepbound competing in China are the main threat to that condition.
As of February 2025, China hosted 60-70 late-stage GLP-1 pipeline assets competing across diabetes and weight-loss indications.
Product Overview
What does the product do for its buyer, and how is it delivered?
Visepegenatide (PB-119) lets physicians in China treat type 2 diabetes and obesity with a long-acting GLP-1 receptor agonist injected once weekly as first-line therapy, a single formulation that requires no dose titration. PegBio independently developed the drug as a Class 1 new medicine.
Approved GLP-1 therapies today are mainly peptide-based injectables, and once-weekly dosing is the prevailing administration approach.